Study / PEM label(s)	PEM description	Availability
Austin 2003 / HERS trial report	Publication in peer‐reviewed journal:   HERS: Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605‐13	HERS is available
Austin 2004‐A / WHI trial report	Publication in peer‐reviewed journal:   Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288:321‐33	WHI is available
Austin 2004‐B / ALLHAT trial report	Publication in peer‐reviewed journal:   ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  JAMA 2002;288:2981‐97	ALLHAT is available
Austin 2005 / REVERSAL, PROVE IT–TIMI22 trials reports	2 publications in peer‐reviewed journals:   REVERSAL: Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, for the REVERSAL Investigators. Effect of intensive compared with moderate lipid‐lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071–80   PROVEIT‐TIMI22: Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495‐504	REVERSAL, PROVE IT–TIMI22 are available
Avorn 1983 / FDA Bulletin	Bulletin patterned after the Federal Drug Administration Drug Bulletin describing alternatives to targeted drugs	Not available
Azocar 2003 / UBH guidelines	US United Behavioral Health (UBH) best practice guidelines for the treatment of major depression	Not available
Barbaglia 2009 / WHI trial report	Publication in peer‐reviewed journal:   Writing Group for the Women’s Health Initiative Investigators. Risk and benefits of estrogens plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002;288:321‐33	WHI is available
Beaulieu 2004 / Guidelines summary	1 page summary of Quebec provincial guidelines (Canada) for anti‐anginal therapy	Not available
Bearcroft 1993/ UK guidelines	Guidelines for referrals for chest radiography for general practitioners	Not available
Bjornson 1990 / VA trial report	Publication in peer‐reviewed journal:   Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 986;314:1547‐52	VA available
Black 2002 / EHC‐OM	EHC‐OM: National Health Service (NHS). The treatment of persistent glue ear in children. Effective Health Care (Bulletin) November 1992, Number 4	EHC‐OM is available
Buyle 2010/ Belgian guidelines	Belgian guidelines for sequential antibiotic therapy (intravenous to oral with fluoroquinolones) published in Pharmacotherapeutic Committee drug letter (October 2003)	Available
Coopersmith 2002/self‐study module	10‐page self‐study module on risk factors and practice modifications involved in catheter‐related infections  for registered nurses	Not available
Denig 1990/Dutch drug bulletin	Dutch drug bulletin Geneesmiddelenbulletin for physicians and pharmacists	Not available
Dormuth 2004/Canadian drug bulletin	12 issues of the drug bulletin Therapeutics Letter	Not available
Fijn 2000/Dutch national recommendations	Dutch national recommendations on antithrombotic prophylaxis of ischaemic heart disease	Not available
Fonarow 2009/MIRACL, PROVE‐IT TIMI 22, AHA‐AHA‐NS and ACC‐AHA‐STEMI	2 publications in peer‐reviewed journals:   MIRACL: Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711‐8   PROVEIT‐TIMI22: Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495‐504   2 guidelines:   AHA‐AHA‐NS : ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST‐segment elevation myocardial infarction   ACC‐AHA‐STEMI:  ACC/AHA guidelines for the management of patients with ST‐elevation myocardial infarction	MIRACL, PROVE‐IT TIMI 22, AHA‐AHA‐NS, ACC‐AHA‐STEMI are available
Fukuda 2009/Japanese guidelines on breast cancer	Japanese evidence‐based clinical practice guidelines for treatment of early‐stage breast cancer	Not available
Guay 2007 / WHI trial report	Publication in peer‐reviewed journal:   Writing Group for the Women’s Health Initiative Investigators. Risk and benefits of estrogens plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321‐33	WHI is available
Haas 2004 / HERS and WHI trials reports	2 publications in peer‐reviewed journals:   HERS: Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605‐13.   WHI: Writing Group for the Women’s Health Initiative Investigators. Risk and benefits of estrogens plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321‐33	HERS, WHI are available
Hersh 2004 / HERS, HERS II, WHI trials reports	3 publications in peer‐reviewed journals:   HERS: Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA  1998;280:605‐13   HERS II: Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA  2002;288:49‐57   WHI: Writing Group for the Women’s Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321‐33	HERS, HERS II, WHI are available
Jackevicius 2001/4S trial report	Publication in peer‐reviewed journal:   Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383‐9	4S Available
Jameson 2010/ NICE guidelines for orthopaedic surgery	The National Institute for Health and Clinical Excellence's recommendations and guideline on prophylaxis for venous thromboembolism in orthopaedic surgery	Not available
Jousimaa 2002 / Finnish guidelines	Collection of Finnish clinical practice guidelines  for primary and ambulatory care Evidence‐Based Medicine Guidelines (previously Physician's Desk Reference and Database)	Not available
Juurlink 2004 / RALES trial report	Publication in peer‐reviewed journal:   Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709‐17	RALES is available
Kabir 2007 / LIFE, ALLHAT and VALUE trials reports	3 publications in peer‐reviewed journals:   LIFE: Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, deFaire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe‐Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003   ALLHAT: ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–97   VALUE: Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–31	ALLHAT, VALUE, LIFE are available
Kajita 2012/ Japanese guidelines on osteoporosis	Japanese evidence‐based guideline Evidence‐based guideline for the prevention of osteoporosis and osteoporotic fractures in community health	Not available
Kottke 1989/Smoking cessation booklet	Smoking cessation booklet Quit‐and‐win	Available
Lam 2009 / 4D trial report	Publication in peer‐reviewed journal:   Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238–48	4D is available
Majumdar 2003/ HOPE and RALES trials reports	2 studies published in peer‐reviewed journals:   HOPE study published in: The Heart Outcomes Prevention Evaluation Study (HOPE): Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. N Engl J Med 2000;342:145–53 Francis GS. ACE inhibition in cardiovascular disease. N Engl J Med 2000;342:201–2 Randomized Aldactone Evaluation Study (RALES): Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709‐17 Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999;341:753–5	HOPE and RALES trials publications are available Available
Majumdar 2004 / WHI trial report	Publication in peer‐reviewed journal:   Writing Group for the Women’s Health Initiative Investigators. Risk and benefits of estrogens plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002;288:321‐33	WHI is available
Mason 1998 / EHC‐D	EHC‐D: National Health Service (NHS). The treatment of depression in primary care. Effective Health Care (Bulletin) March 1993, Number 5	EHC‐D is available
Mason 2001 / EHC‐OM	EHC‐OM: National Health Service (NHS). The treatment of persistent glue ear in children. Effective Health Care (Bulletin) November 1992, Number 4	EHC‐OM is available
Matowe 2002/ UK Royal college of radiologists guidelines	Royal College of Radiologists. Making the Best Use of a Department of Radiology: Guidelines for Doctors. London: Royal College of Radiologists, 1998	Not available
Meyer 2007/ German guidelines for the ICU	Guidelines on empirical antibiotic treatment in the Intensive Care Unit (ICU)	Not available
Oakeshott 1994/UK Royal college of radiologists guidelines	Royal College of Radiologists. Making the Best Use of a Department of Radiology: Guidelines for Doctors. London: Royal College of Radiologists, 1990	Not available
Perria 2007/ Italian guidelines	Italian evidence‐based guidelines for the management of non‐complicated type 2 diabetes mellitus	Not available
Roberts 2007/NICE guidelines for primary hip replacement	National Institute for Health and Clinical Excellence (NICE).  Guidelines on the Selection of Prostheses for Primary Hip Replacement. London: NHS, April 2000	Available
Santerre 1996/ACOG guidelines	American College of Obstetricians and Gynecologists (ACOG) clinical management guidelines for vaginal birth after cesarean delivery (VBAC)	Not available
Shah 2008/Nissen and al. study report	Publication in peer‐reviewed journal:   Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 2007;356:2457–71	Available
Stafford 2004 / ALLHAT trial report	Publication in peer‐reviewed journal:   ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981‐97	ALLHAT is available
Tsuji  2009/Guidelines for physician depression	Depression diagnosis and treatment guide for primary care physicians	Not available
Wang 2005/ADA and ATP III trials reports	ADA: American Diabetes Association (ADA) guidelines published in January 1998 advocated an LDL cholesterol goal under 100 mg/dl for patients with diabetes   Publication in peer‐reviewed journal:   ATP III: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in  Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97	ATP III is available
Watson 2001/Guidelines for musculoskeletal disorder	Guidelines for the use of oral Non‐Steroidal Antiinflammatory drugs (NSAIDs) in the management of musculoskeletal disorders	Available:   Watson M. The Development, Implementation And Evaluation Of Prescribing Guidelines In General Practice. 1998; PhD Thesis   Algorithm
Weiss 2011/Quebec guidelines on antibiotics	Eleven 2‐page graphic user‐friendly guidelines providing clinical information  and antibiotic recommendations	Available